Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6798)	8/1/1998 8:37:00 AM
From: Robert S.	Read Replies (2) \| Respond to of 17367

BAYER AG ANNOUNCES ESTABLISHMENT OF INTERNATIONAL SEPSIS FORUM (ISF) ''We expect that the ISF will provide resources and support for new ideas that will help shape the future of the treatment and management of sepsis and septic shock,'' said Professor Dr. Dieter Maruhn, Head of Anti-Infectives Product Development at Bayer. But, George, as you stated earlier "Bayers sepsis trial failed. Bayer is aware of Xoma's work in this area. Bayer would be a logical partner". Bayer is aware of xoma's Phase III trials, yet they state that new ideas and approaches are still desired. I do not, IMHO, view this as a vote of confidence in xoma's products for sepsis. You seem to think differently. Why?